{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:27:21Z","timestamp":1783636041994,"version":"3.55.0"},"reference-count":22,"publisher":"Hindawi Limited","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mediators of Inflammation"],"published-print":{"date-parts":[[2016]]},"abstract":"Background.<\/jats:italic>Inflammation plays a key role in cancer. In the current study, we proposed a novel inflammation-based stage, named I stage, for patients with resectable esophageal squamous cell carcinoma (ESCC).Methods<\/jats:italic>. Three hundred and twenty-three patients with resectable ESCC were enrolled in the current study. The I stage was calculated as follows: patients with high levels of C-reactive protein (CRP) (>10\u2009mg\/L), neutrophil-to-lymphocyte ratio (NLR) (>3.5), and platelet-count-to-lymphocyte ratio (PLR) (>150) were defined as I3. Patients with two, one, or no abnormal value were defined as I2, I1, or I0, respectively. The prognostic factors were evaluated by univariate and multivariate analyses.Results.<\/jats:italic>There were 112 patients for I0, 97 patients for I1, 66 patients for I2, and 48 patients for I3, respectively. The 5-year cancer-specific survival (CSS) in patients with I0, I1, I2, and I3 was 50.0%, 30.9%, 18.2%, and 8.3%, respectively (I0 versus I1,P<\/mml:mi>=<\/mml:mo>0.002<\/mml:mn><\/mml:math>; I1 versus I2,P<\/mml:mi>=<\/mml:mo>0.012<\/mml:mn><\/mml:math>; I2 versus I3,P<\/mml:mi>=<\/mml:mo>0.020<\/mml:mn><\/mml:math>). Multivariate analyses revealed that I stage was an independent prognostic factor in patients with resectable ESCC (P<\/mml:mi><<\/mml:mo>0.001<\/mml:mn><\/mml:math>).Conclusion<\/jats:italic>. The inflammation-based stage (I stage) is a novel and useful predictive factor for CSS in patients with resectable ESCC.<\/jats:p>","DOI":"10.1155\/2016\/5396747","type":"journal-article","created":{"date-parts":[[2016,4,26]],"date-time":"2016-04-26T21:01:23Z","timestamp":1461704483000},"page":"1-8","source":"Crossref","is-referenced-by-count":9,"title":["A Novel Inflammation-Based Stage (I Stage) in Patients with Resectable Esophageal Squamous Cell Carcinoma"],"prefix":"10.1155","volume":"2016","author":[{"given":"Peng-Cheng","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou 310022, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Feng","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou 310022, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21254"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.2188\/jea.je20120162"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1007\/s13193-013-0216-0"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(00)04046-0"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1038\/nature07205"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-015-3464-5"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.3109\/1354750X.2014.926567"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1007\/s00595-009-4297-x"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1002\/jso.23424"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1302\/0301-620x.95b3.30344"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.09.004"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1002\/jso.10275"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7819-8-1"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-011-1411-1"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-011-1754-8"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-011-1130-7"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7819-12-58"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25146"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9629(15)40692-5"},{"key":"20","first-page":"2180","volume":"5","year":"2015","journal-title":"American Journal of Cancer Research"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000251703.35919.02"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1097\/sla.0b013e318188c474"}],"container-title":["Mediators of Inflammation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/mi\/2016\/5396747.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/mi\/2016\/5396747.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/mi\/2016\/5396747.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,7,26]],"date-time":"2016-07-26T16:36:28Z","timestamp":1469550988000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.hindawi.com\/journals\/mi\/2016\/5396747\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":22,"alternative-id":["5396747","5396747"],"URL":"https:\/\/doi.org\/10.1155\/2016\/5396747","relation":{},"ISSN":["0962-9351","1466-1861"],"issn-type":[{"value":"0962-9351","type":"print"},{"value":"1466-1861","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}